Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reconstructing immunity after allogeneic transplantation.

Cynthia R Giver1, Jian-Ming Li, Mohammad S Hossain

  • 1Blood Cell Therapy Laboratory, Winship Cancer Institute, Emory University, 1365C Clifton Road, Rm. 4002, Atlanta, GA 30322, USA.

Immunologic Research
|June 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia-driven T cell-macrophage-stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease.

Science translational medicine·2026
Same author

T cell-macrophage crosstalk in GVHD and cancer immunotherapy.

Cell investigation·2026
Same author

Vancomycin-Tacrolimus Combination-Related Acute Kidney Injury Risk in Posthematopoietic Stem Cell Transplant Patients.

Transplantation and cellular therapy·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease.

Transplantation and cellular therapy·2026
Same author

Dysbiosis and gastrointestinal GVHD: to treat or not to treat.

Blood·2026

This study shows that donor memory CD4 T cells can rebuild the immune system after bone marrow transplants without causing graft-vs-host disease (GVHD). Manipulating dendritic cells in grafts improved graft-vs-tumor (GVT) effects while limiting GVHD.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Oncology

Background:

  • Graft-vs-host disease (GVHD) and graft-vs-tumor (GVT) effects are critical outcomes in allogeneic bone marrow transplantation (BMT).
  • Modulating donor immune cell populations ex vivo is a strategy to mitigate GVHD while preserving GVT.

Purpose of the Study:

  • To investigate the distinct roles of donor T cell subsets and dendritic cells (DCs) in mediating GVHD and GVT.
  • To identify methods for improving the therapeutic index of allogeneic BMT by separating beneficial GVT from detrimental GVHD.

Main Methods:

  • Utilized allogeneic mouse models of BMT.
  • Employed ex vivo cell manipulation techniques, including T cell subset isolation and DC content modulation via CD11b+ cell depletion.
  • Analyzed the impact of different donor immune cell populations on GVHD and GVT outcomes.

Related Experiment Videos

Main Results:

  • Donor memory CD4 T cells promoted immune reconstitution without GVHD, unlike naive CD4 T cells which caused fatal GVHD.
  • Increased donor type 2 DCs correlated with reduced chronic GVHD but increased relapse in clinical BMT.
  • Depletion of CD11b+ cells from bone marrow grafts enhanced memory T cell expansion, improved GVT, and reduced GVHD in mice.

Conclusions:

  • Donor memory CD4 T cells are key for safe immune reconstitution post-BMT.
  • Modulating donor DCs and T cell subsets offers a promising strategy to enhance GVT and minimize GVHD.
  • A model is proposed where T-cell subset and DC subset interactions dictate GVT vs. GVHD outcomes.